Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2441162rdf:typepubmed:Citationlld:pubmed
pubmed-article:2441162lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C0003015lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C0232105lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:2441162lifeskim:mentionsumls-concept:C0141227lld:lifeskim
pubmed-article:2441162pubmed:issue2lld:pubmed
pubmed-article:2441162pubmed:dateCreated1987-9-24lld:pubmed
pubmed-article:2441162pubmed:abstractTextS-9780 is the active diacid metabolite of the new angiotensin-converting enzyme (ACE) inhibitor perindopril. In a double-blind, randomised, crossover study, the effects of 1, 2, and 4 mg of S-9780 administered intravenously (i.v.) were compared with placebo in eight normotensive subjects. All active doses caused immediate, maximal, and similar inhibition of plasma ACE with 40% inhibition persisting after 48 h. Plasma renin activity was elevated 4 and 8 h after dosing, but no effect on plasma aldosterone, adrenaline or noradrenaline levels was detected. Diastolic blood pressure was lowered by 4 mg of S-9780 until 24 h after dosing. Heart rate did not change. The pharmacokinetics of S-9780 fitted a three-compartment model with a terminal half-life (t1/2) of 31 h. Inhibition of plasma ACE was closely related to observed drug concentration, with 1.8 +/- 0.9 ng/ml (mean +/- S.D.) producing 50% inhibition of the enzyme. S-9780 caused predictable effects on the cardiovascular and renin angiotensin systems.lld:pubmed
pubmed-article:2441162pubmed:languageenglld:pubmed
pubmed-article:2441162pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441162pubmed:citationSubsetIMlld:pubmed
pubmed-article:2441162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441162pubmed:statusMEDLINElld:pubmed
pubmed-article:2441162pubmed:monthAuglld:pubmed
pubmed-article:2441162pubmed:issn0160-2446lld:pubmed
pubmed-article:2441162pubmed:authorpubmed-author:ReidJ LJLlld:pubmed
pubmed-article:2441162pubmed:authorpubmed-author:LeesK RKRlld:pubmed
pubmed-article:2441162pubmed:issnTypePrintlld:pubmed
pubmed-article:2441162pubmed:volume10lld:pubmed
pubmed-article:2441162pubmed:ownerNLMlld:pubmed
pubmed-article:2441162pubmed:authorsCompleteYlld:pubmed
pubmed-article:2441162pubmed:pagination129-35lld:pubmed
pubmed-article:2441162pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:meshHeadingpubmed-meshheading:2441162-...lld:pubmed
pubmed-article:2441162pubmed:year1987lld:pubmed
pubmed-article:2441162pubmed:articleTitleEffects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects.lld:pubmed
pubmed-article:2441162pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2441162pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2441162pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2441162pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2441162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2441162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2441162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2441162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2441162lld:pubmed